Hepatocellular Carcinoma News and Research

RSS

Hepatocellular Carcinoma is a type of adenocarcinoma, the most common type of liver tumor.

Delisheng shows anti-cancer effects on hepatocellular carcinoma

Traditional Chinese medicine is world renowned. It has supernatural effects on some diseases, but the reason is still unknown. One such article was recently reported in the November 7 issue of the World Journal of Gastroenterology dealing with the great significance of a Chinese medicinal compound, "delisheng", for the therapy of HCC and its neoteric research method.

16 Oct 2007

Proteins found that could be used to improve diagnosis of hepatocellular carcinoma

Researchers report in the October 2007 issue of Molecular & Cellular Proteomics that they have identified proteins that could be used to improve the diagnosis of hepatocellular carcinoma, the most common type of liver cancer.

8 Oct 2007

FDA fast tracks PI-88 for the treatment of post resection liver cancer

Progen Pharmaceuticals Limited has announced that its investigational anti-cancer drug PI-88 has been awarded Fast Track status by the U.S. Food and Drug Administration (FDA).

25 Sep 2007

Nerve growth factor positively related with liver cancer - potential therapy target

Nerve growth factor (NGF), as the name says, is an essential peptide factor for the growth and differentiation of neuronal cells.

20 Sep 2007

Liver cancer marker could yield blood test for early detection

In the face of an emerging liver cancer crisis in Asia, researchers at the Chinese University of Hong Kong have developed a test that could help millions.

18 Sep 2007

New test to detect early stage liver cancer

Cancer of the liver is very difficult to detect, and it is a major cause of death in Asia and Africa, with rising incidence in Western countries as well.

9 Aug 2007

Coffee and liver cancer

After lung and stomach cancer, liver cancer is the third largest cause of cancer deaths in the world.

2 Aug 2007

Bayer and Onyx submit supplemental NDA for Nexavar

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have announced that a Supplemental New Drug Application (sNDA) for Nexavar (sorafenib) tablets has been submitted to the U.S. Food and Drug Administration (FDA) for the treatment of patients with hepatocellular carcinoma (HCC), the most common form of liver cancer. Nexavar is currently approved in more than 50 countries for the treatment of advanced kidney cancer.

28 Jun 2007

New contributor to aggressive cancers

Mutations in the cell adhesion molecule known as integrin alpha 7 (integrin 7) lead to unchecked tumor cell proliferation and a significantly higher incidence in cancer spread, or metastasis, in several cancer cell lines, report researchers at the University of Pittsburgh School of Medicine in a study published in the Journal of the National Cancer Institute.

8 Jun 2007

Liver cancer patients with high serum levels of hepatitis B virus face poorer outcomes

In the June issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD), researchers report their findings from the first-ever study examining the prognostic value of serum HBV DNA levels for patients with liver cancer undergoing chemotherapy.

3 Jun 2007

Percutaneous radiofrequency ablation of liver tumors safe and effective

Percutaneous imaging guided radiofrequency ablation (RFA) of hepatocellular carcinoma is a safe and effective technique, with benefits such as reduced post-procedural pain and length of hospital stay, according to a study conducted by researchers from Changi General Hospital in Singapore.

8 May 2007

Potential biomarkers for early detection of liver cancer

Researchers at Columbia University's Mailman School of Public Health have discovered a means for early detection of liver cancer.

16 Apr 2007

CuraGen announces results with Belinostat and Velafermin

CuraGen Corporation has announced that new preclinical data on belinostat (PXD101), a histone deacetylase (HDAC) inhibitor being investigated for the treatment of cancer, and velafermin, a protein being investigated for the prevention of severe oral mucositis, will be presented at the upcoming American Association for Cancer Research (AACR) 2007 Annual Meeting in Los Angeles, CA, April 14-18, 2007.

15 Apr 2007

Cost-effectiveness analysis of variceal ligation vs. beta-blockers for primary prevention of variceal bleeding

Endoscopic variceal ligation is cost-effective relative to beta-blockers for the prevention of variceal bleeding in cirrhotic patients if quality of life-years are considered.

4 Apr 2007

NAFLD fibrosis score helps predict advanced fibrosis in patients with nonalcoholic fatty liver disease

Certain routine demographic, clinical, and laboratory values can be used to identify advanced fibrosis in patients with nonalcoholic fatty liver disease (NAFLD).

4 Apr 2007

Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes

Researchers open the way for improved study of hepatitis C virus by devising a novel virus culture system that allows replication of patient-isolated virus in nontransformed hepatocytes, instead of culture-adapted virus strains in transformed cell lines.

23 Jan 2007

Nanoparticles from crab shells show promise for drug delivery

Nanoparticles made of chitosan, a naturally occuring polymer isolated from crab and shrimp shells, have shown promise as carriers of anticancer drugs, antitumor genes, and other novel therapeutic agents.

22 Jan 2007

Colchicine delays development of hepatocellular carcinoma in patients with hepatitis virus-related liver cirrhosis

Colchicine, an anti-inflammatory drug most often used to treat gout, prevented liver cancer in patients with hepatitis virus-related end-stage liver disease, according to a new study.

11 Sep 2006

Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma

The results of this study appear in the August 2006 issue of Liver Transplantation, the official journal of the American Association for the Study of Liver Diseases (AASLD) and the International Liver Transplantation Society (ILTS).

2 Aug 2006

Nexavar approved in Europe for treatment of advanced kidney cancer

Bayer Pharmaceuticals Corporation and Onyx Pharmaceuticals, Inc have announced that the European Commission has granted marketing authorization to Nexavar (sorafenib) tablets for the treatment of patients with advanced renal cell carcinoma.

24 Jul 2006